What are the drugs for nasopharyngeal carcinoma

The treatment of nasopharyngeal carcinoma mainly includes chemotherapy drugs, targeted therapy drugs and immunotherapy drugs. Common chemotherapy drug regimens include cisplatin combined with 5-fluorouracil, carboplatin combined with paclitaxel, docetaxel combined with carboplatin, etc. Targeted therapy drugs such as cetuximab are often used in combination with chemotherapy. Immunotherapy drugs such as pembrolizumab are suitable for patients with positive PD-L1 expression and ineffective chemotherapy.

1. Chemotherapy drugs are the basis of nasopharyngeal carcinoma treatment. Cisplatin combined with 5-fluorouracil can effectively kill tumor cells, carboplatin combined with paclitaxel can enhance drug permeability, and docetaxel combined with carboplatin can improve efficacy and reduce side effects. Chemotherapy drugs are administered intravenously or orally, and blood routine and liver and kidney function tests need to be checked regularly.

2. Targeted therapy drug cetuximab inhibits tumor growth and metastasis by inhibiting the EGFR signaling pathway. Combining it with chemotherapy can improve efficacy. Common side effects include rash and diarrhea. EGFR expression testing is required before use, and adverse reactions need to be closely monitored during use.

3. The immunotherapy drug pembrolizumab activates the patient's own immune system to attack tumor cells. It is suitable for patients with positive PD-L1 expression and ineffective chemotherapy, and can prolong survival. Common side effects include fatigue, rash, etc., and immune-related adverse reactions need to be monitored regularly.

The treatment of nasopharyngeal carcinoma requires a personalized plan based on the patient's specific situation, including drug selection, dose adjustment, and side effect management. Regular follow-up is required during treatment to evaluate the efficacy and adjust the treatment plan. Early detection and timely treatment are crucial to improving the cure rate and quality of life.